Anaconda BioMed is thrilled to announce a significant funding milestone, having successfully raised $25,000,000 to drive our mission of transforming health through innovation and advanced research. At the heart of our work is a profound understanding that health encompasses the level of functional or metabolic efficiency of a living organism, empowering humans to adapt and self-manage when facing physical, mental, or social challenges. This substantial capital injection will be strategically channeled into accelerating research and development, driving groundbreaking clinical solutions, and expanding our product portfolio to address the multifaceted nature of health. With these funds, we are poised to deepen our engagement with pioneering technologies that enhance the resilience of both individuals and communities facing evolving health challenges. By bolstering our operational capabilities and reinforcing our scientific expertise, Anaconda BioMed aims to solidify its position as a leader in healthcare innovation, dedicated to improving outcomes across a spectrum of disorders and conditions. In addition, this funding will support critical collaborations with academic institutions, healthcare providers, and industry leaders, further integrating comprehensive, multidimensional approaches into our portfolio. We believe that robust, adaptive healthcare systems are vital in today’s dynamic world, and our renewed commitment is designed to meet these demands head-on. The journey ahead is inspiring, and this investment signals a transformative era for Anaconda BioMed as we strive to empower communities and redefine the standards of health with advanced, accessible, and sustainable healthcare solutions.
Anaconda BioMed Secures $25M Series C Funding to Boost Health Resilience and Innovation
Recently funded · €25.0M Series cMedical Devices
Get the full Anaconda BioMed company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
